Microvascular Obstruction after Successful Fibrinolytic Therapy in Acute Myocardial Infarction. Comparison of Reteplase vs Reteplase+Abciximab: A Cardiovascular Magnetic Resonance Study

Abstract

Background.

About one third of patients with TIMI 3 after reperfusion have evidence of microvascular obstruction (MO) which represents an independent predictor of myocardial wall rupture. This explains all efforts made to prevent MO. Magnetic resonance imaging (MRI) has proved to be particularly useful in detecting MO. The aim of this study was to evaluate with MRI if different fibrinolytic regimens in acute myocardial infarction display different effects on left ventricle (LV) volumes and ejection fraction (EF), as well as on myocardial infarct size (MIsz) and MO.

Methods.

Twenty male patients, mean age 58 years, affected by acute myocardial infarction, ten anterior and ten inferior, were treated with: full dose reteplase in ten, and half dose reteplase plus full dose abciximab (R+Abcx) in the other ten patients. In the fourth day after hospital admission, MRI STIR T2 images were used to quantify MIsz, while 2dflash cineloops were used after the injection of gadolinium, to quantify LV volumes, EF and to detect MO.

Results.

LV EF was higher in R+Abcx 51 ±10 than in reteplase 41±8. MIsz was similar in both treatment groups: however a close relationship was present between MIsz and EF in the reteplase group indicating that the greater the MIsz the lower the EF. In R+Abcx this relationship was no longer present, suggesting a protective effect of the drug on microcirculation. In fact extensive MO was present in 25% of all cases, 80% of which in the reteplase group while only 20% in R+Abcx.

Conclusion.

R+Abcx prevents MO: compared to traditional fibrinolytic therapy it allows better LV function and most likely improved long term survival.

Keywords

Magnetic resonance Myocardial infarction Microvascular obstruction

Get full access to this article

View all access options for this article.

References

Neumann

F.J.

Optimization of microvascular reperfusion in acute myocardial infarction.

European Heart Journal Supplements 2001; 3(Suppl A), A21–5.

Kaul

, Ito

Microvasculature in acute myocardial ischemia: Part I and part II evolving concepts in pathophysiology, diagnosis, and treatment.

Circulation 2004; 109: 146–9: 310–5.

Christiansen

J.P.

, Leong-Poi

, Klibanov

A.L.

Noninvasive imaging of myocardial reperfusion injury using leukocyte-targeted contrast echocardiography

circulation 2002; 105: 1764–7.

Ragosta

, Camarano

G.P.

, Kaul

Microvascular integrity indicates myocellular viability in patients with recent myocardial infarction: New insights using myocardial contrast echocardiography.

Circulation 1994; 89: 2562–9.

Ito

, Okamura

, Iwakura

Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction.

Circulation 1996; 93: 1993–9.

Asanuma

, Tanabe

, Ochiai

Relationship between progressive microvascular damage and intramyocardial hemorrhage in patients with reperfused anterior myocardial infarction: Myocardial contrast echocardiographic study.

Circulation 1997; 96: 448–53.

Reffelmann

, Kloner

R.A.

Anatomic no reflow during reperfusion in the rabbit.

AJP – Heart 2002; 283: 1099–107.

Zoni

, Arisi

, Corradi

Magnetic resonance imaging of impending left ventricular rupture after acute myocardial infarction.

Circulation 2003; 108: 498–9.

Henriques

J.P.S.

, Zijlstra

, Ottervanger

J.P.

Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction.

European Heart Journal 2002; 23: 1112–7.

10.

Davies

M.J.

, Thomas

A.C.

, Knapman

P.A.

Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death.

Circulation 1986; 73: 418–27.

11.

Frink

R.J.

, Rooney

P.A.

, Trowbridge

J.O.

Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction.

Br Heart J 1988; 59: 196–200.

12.

Rochitte

C.E.

, Lima

J.A.C.

, Bluemke

D.A.

Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction.

Circulation 1998; 98: 1006–14.

13.

Bremerich

, Wendland

M.F.

, Arheden

Microvascular injury in reperfused infarcted myocardium: Noninvasive assessment with contrast-enhanced echoplanar magnetic resonance imaging.

J Am Coll Cardiol 1998; 32: 787–93.

14.

Reffelmann

No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion circulation. 2003; 108: 2911–7.

15.

Jugdutt

B.I.

Ventricular remodeling after infarction and the extracellular collagen matrix: When is enough enough?

Circulation 2003; 108: 1395–403.

16.

K.C.

, Zerhouni

E.A.

, Judd

R.M.

Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction.

Circulation 1998; 97: 765–72.

17.

Limbruno

, Micheli

, De Carlo

Mechanical prevention of distal embolization during primary angioplasty: Safety, feasibility, and impact on myocardial reperfusion.

Circulation 2003; 108: 171–6.

18.

Sangiorgi

, Colombo

Embolic protection devices.

Heart 2003; 89: 990–2.

19.

Piana

R.N.

, Paik

G.Y.

, Moscucci

Incidence and treatment of “no reflow” after percutaneous coronary intervention.

Circulation 1994; 89: 2514–8.

20.

Ishihara

, Sato

, Tateishi

Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine.

Am Heart J 1996; 132: 959–63.

21.

Neumann

F-J

, Kenngott

, Gawaz

, Schomig

Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction.

Am J Cardiol 1998; 82: 938–42.

22.

Taniyama

, Ito

, Iwakura

Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction.

J Am Coll Cardiol 1997; 30: 1193–9.

23.

Meisel

S.R.

, Shapiro

, Radnay

Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: Possible implications for leukocyte aggregation and microvascular plugging.

J Am Coll Cardiol 1998; 31: 120–5.

24.

Neumann

F-J

, Blasini

, Schmitt

Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction.

Circulation 1998; 98: 2695–701.

25.

Mahaffey

K.W.

, Puma

J.A.

, Barbagelata

Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial-the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial.

J Am Coll Cardiol 1999; 34: 1171–20.

26.

Ito

, Taniyama

, Iwakura

Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction.

J Am Coll Cardiol 1999; 33: 654–60.

27.

de Lemos

J.A.

, Antman

E.M.

, Gibson

C.M.

Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 trial.

Circulation 2000; 101: 239–43.

28.

Sato

, Sasaki

, O'Rourke

Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels.

J Am Coll Cardiol 2000; 35: 514–8.

29.

The GUSTO V Investigators.

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination low dose fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V Trial

Lancet 2001; 357: 1905–14.

30.

Lincoff

A.M.

, Califf

R.M.

, van de Werf

, for the GUSTO V Investigators. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy versus conventional fibrinolytic therapy for acute myocardial infarction: The GUSTO V randomized trial. JAMA 2002; 288: 2130–5.

31.

Sakuma

, Leong-Poi

, Fisher

N.G.

Further insights into the “no-reflow” phenomenon after primary angioplasty in acute myocardial infarction: The role of microthromboemboli.

J Am Soc Echocardiogr 2003; 16: 15–21.

32.

Galiuto

Optimal therapeutic strategies in the setting of post-infarct no reflow: The need for a pathogenetic classification.

Heart 2004; 90: 123–5.

33.

Steen

, Lehrke

, Wiegand

U.K.H.

Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction.

Am Heart J 2005; 149: 564–4.

34.

Yamamuro

Coronary flow velocity pattern immediately after percutaneous coronary intervention as a predictor of complications and in-hospital survival after acute myocardial infarction.

Circulation 2002; 106: 3051–6.

35.

Furber

A.P.

, Prunier

, Cuong

, Nguyen

Coronary blood flow assessment after successful angioplasty for acute myocardial infarction predicts the risk of long-term cardiac events.

Circulation 2004; 110: 3527–33.

36.

Rogers

W.J.

, Kramer

C.M.

, Geskin

Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction.

Circulation 1999; 99: 744–50.

37.

Rochitte

C.E.

, Kim

R.J.

, Hillenbrand

H.B.

Microvascular integrity and the time course of myocardial sodium accumulation after acute infarction.

Circ Res 2000; 87: 648–55.

38.

Miller

, Helber

, Kramer

Subacute myocardial infarction: Assessment by STIR T2-weighted MR imaging in comparison to regional function.

Magnetic Resonance Materials in Physics, Biology and Medicine 2001; 13: 8–14.

39.

Ramani

, Judd

R.M.

, Holly

T.A.

Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction.

Circulation 1998; 98: 2687–94.

40.

Gerber

B.L.

, Rochitte

C.E.

, Melin

J.A.

Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction.

Circulation 2000; 101: 2734–41.

41.

Kramer

C.M.

, Rogers

W.J.

, Mankad

Contractile reserve and contrast uptake pattern by magnetic resonance imaging and functional recovery after reperfused myocardial infarction.

J Am Coll Cardiol 2000; 36: 6.

42.

Miller

, Schicka

, Scheule

A.M.

Conventional high resolution versus fast T2-weighted MR imaging of the heart: Assessment of reperfusion induced myocardial injury in an animal model.

Magn Reson Imaging 2000; 18: 1069–77.

43.

Gerber

B.L.

, Rochitte

C.E.

, Bluemke

D.A.

Relation between Gd-DTPA contrast enhancement and regional inotropic response in the periphery and center of myocardial infarction.

Circulation 2001; 104: 998–1004.

44.

Taylor

A.J.

, Al-Saadi

, Abdel-Aty

Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging.

Circulation 2004; 109: 2080–5.

45.

ACCF/AHA Clinical competence statement on cardiac imaging with computed tomography and magnetic resonance. J Am Coll Cardiol 2005; 46: 2.

46.

Pennell

D.J.

, Sechtem

U.P.

, Higgins

C.B.

Clinical indications for cardiovascular magnetic resonance: Consensus panel report.

Eur Heart J 2004; 25: 1940–65.

47.

Ito

, Tomooka

, Sakai

Lack of myocardial perfusion immediately after successful thrombolysis: A predictor of poor recovery of left ventricular function in anterior myocardial infarction.

Circulation 1992; 85: 1699–705.

48.

Schwitter

, Saeed

, Wendland

M.F.

Influence of the severity of myocardial injury on the distribution of macromolecules: Extra versus intra-vascular gadolinium-based MR contrast agents.

J Am Coll Cardiol 1997; 30: 1086–94.

49.

K.C.

, Kim

R.J.

, Bluemke

D.A.

Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion.

J Am Coll Cardiol 1998; 32: 1756–64.

50.

K.C.

, Zerhouni

E.A.

, Judd

R.M.

Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction.

Circulation 1998; 97: 765–72.

51.

Bremerich

, Wendland

M.F.

, Arheden

Microvascular injury in reperfused infarcted myocardium: Noninvasive assessment with contrast-enhanced echoplanar magnetic resonance imaging.

J Am Coll Cardiol 1998; 32: 787–93.

52.

Saeed

, van Dijke

C.F.

, Mann

J.S.

Histologic confirmation of microvascular permeability to macromolecular MR contrast medium in reperfused myocardial infarction.

J Magn Reson Imaging 1998; 8: 561–7.

53.

Ochiai

, Shimada

, Murakami

Hemorrhagic myocardial infarction after coronary reperfusion detected in vivo by magnetic resonance imaging in humans: Prevalence and clinical implications.

J Cardiovasc Magn Reson 1999; 1: 247–56.

54.

Miller

, Schicka

, Scheuleb

A.M.

Conventional high resolution versus fast T2-weighted MR imaging of the heart: Assessment of reperfusion induced myocardial injury in an animal model.

Magn Reson Imaging 2000; 18: 1069–77.

55.

Lesser

J.R.

, Johnson

, Lindberg

J.L.

Myocardial rupture, microvascular obstruction, and infarct expansion: Elucidation by cardiac magnetic resonance.

Circulation 2003; 108: 116–7.

56.

Ibrahim

, Nekolla

S.G.

, Hörnke

Quantitative measurement of infarct size by contrast-enhanced magnetic resonance imaging early after acute myocardial infarction.

J Am Coll Cardiol 2005; 45: 544–52.

57.

Bottini

, Carr

, Prisant

, Flickinger

, Allison

, Gottdiener

Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient.

Am J Hypertens 1995; 8: 221–2.

58.

Bellenger

N.G.

, Francis

J.M.

, Davies

L.C.

, Coats

A.J.S.

, Pennell

D.J.

Establishment and performance of a magnetic resonance cardiac function clinic.

J Cardiovasc Magn Reson 1999; 1: 323–30.

59.

Bellenger

N.G.

, Davies

L.C.

, Francis

J.M.

, Coats

A.C.S.

, Pennell

D.J.

Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance.

J Cardiovasc Magn Reson 2000; 2: 271–8.

60.

Salton

C.J.

, Chuang

M.L.

, O'Donnell

C.J.

Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring Cohort.

J Am Coll Cardiol 2002; 39: 1055–60.

61.

Grothues

, Smith

G.C.

, Moon

J.C.

Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy.

Am J Cardiol 2002; 90: 29–34.

62.

Bellenger

N.G.

, Swinburn

J.M.A.

, Rajappan

Cardiac remodelling in the era of aggressive medical therapy: Does it still exist?

Int J Cardiol 2002; 83: 217–25.

63.

Tarantini

, Cacciavillani

, Corbetti

Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty. A study performed with contrast-enhanced magnetic resonance.

J Am Coll Cardiol 2005; 46: 1229–35.

64.

Lim

T.H.

, Hong

, Lee

J.S.

Novel application of breath-hold turbo spin-echo T2 MRI for detection of acute myocardial infarction.

J Magn Reson Imag 1997; 7: 966.

65.

Pislaru

S.V.

, Ni

, Pislaru

Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent.

Circulation 1999; 99: 690–6.

66.

Miller

, Schicka

, Scheule

A.M.

Conventional high resolution versus fast T2-weighted MR imaging of the heart: Assessment of reperfusion induced myocardial injury in an animal model.

Magn Reson Imaging 2000; 18: 1069–77.

67.

Miller

, Helber

, Kramer

Subacute myocardial infarction: Assessment by STIR T2-weighted MR imaging in comparison to regional function.

Magnetic Resonance Materials in Physics, Biology and Medicine 2001; 13: 8–14.

68.

Abdel-Aty

, Zagrosek

, Schulz-Menger

Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction.

Circulation 2004; 109: 2411–6.

69.

Kim

R.J.

, Chen

E.L.

, Lima

J.A.

, Judd

R.M.

Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction.

Circulation 1996; 94: 3318–26.

70.

Kim

R.J.

, Fieno

D.S.

, Parrish

T.B.

Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function.

Circulation 1999; 100: 1992–2002.

71.

Saeed

, Bremerich

, Wendland

M.F.

Reperfused myocardial infarction as seen with use of necrosis-specific versus standard extracellular MR contrast media in rats.

Radiology 1999; 213: 247–57.

72.

Fieno

D.S.

, Kim

R.J.

, Chen

E.L.

Contrast-enhanced magnetic resonance imaging of myocardium at risk: Distinction between reversible and irreversible injury throughout infarct healing.

J Am Coll Cardiol 2000; 36: 1985.

73.

Simonetti

O.P.

, Kim

R.J.

, Fieno

D.S.

An improved MR imaging technique for the visualization of myocardial infarction.

Radiology 2001; 218: 215–23.

74.

Hillenbrand

H.B.

, Kim

R.J.

, Parker

M.A.

Early assessment of myocardial salvage by contrast-enhanced magnetic resonance imaging.

Circulation 2000; 102: 1678–83.

75.

Sandstede

J.J.

, Lipke

, Beer

Analysis of first-pass and delayed contrast-enhancement patterns of dysfunctional myocardium on MR imaging: Use in the prediction of myocardial viability.

AJR Am J Roentgenol 2000; 174: 1737–40.

76.

Kim

R.J.

, Wu

, Rafael

The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.

N Engl J Med 2000; 343: 1445–53.

77.

Oshinski

J.N.

, Yang

, Jones

J.R.

Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging.

Circulation 2001; 104: 2838–42.

78.

, Judd

R.M.

, Vargas

J.D.

Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction.

Lancet 2001; 357: 21–8.

79.

Choi

K.M.

, Kim

R.J.

, Gubernikoff

Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function.

Circulation 2001; 104: 1101–7.

80.

Mahrholdt

, Wagner

, Holly

T.A.

Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging.

Circulation 2002; 106: 2322–7.

81.

Rehwald

W.G.

, Fieno

D.S.

, Chen

E.L.

Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury.

Circulation 2002; 105: 224–9.

82.

Barkhausen

, Ebert

, Debatin

J.F.

, Weinmann

H.J.

Imaging of myocardial infarction: Comparison of Magnevist and gadophrin-3 in rabbits.

J Am Coll Cardiol 2002; 39: 1392–8.

83.

Gerber

B.L.

, Garot

, Bluemke

D.A.

Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction.

Circulation 2002; 106: 1083–9.

84.

Klein

, Nekolla

S.G.

, Bengel

F.M.

Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: Comparison with positron emission tomography.

Circulation 2002; 105: 162–7.

85.

Petersen

S.E.

, Horstick

, Voigtlander

Diagnostic value of routine clinical parameters in acute myocardial infarction: A comparison to delayed contrast enhanced magnetic resonance imaging. Delayed enhancement and routine clinical parameters after myocardial infarction.

Int J Cardiovasc Imaging 2003; 19: 409–16.

86.

Martin

T.N.

, Groenning

B.A.

, Steedman

A single troponin I concentration measured 12 hours after onset of chest pain accurately reflects infarct size as measured by gadolinium-DTPA late enhancement magnetic resonance imaging.

J Am Coll Cardiol 2003; 41: 380–1.

87.

Kuhl

H.P.

, Beek

A.M.

, van der Weerdt

A.P.

Myocardial viability in chronic ischemic heart disease: Comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography.

J Am Coll Cardiol 2003; 41: 1341–8.

88.

Knuesel

P.R.

, Nanz

, Wyss

Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance.

Circulation 2003; 108: 1095–100.

89.

Beek

A.M.

, Kuhl

H.P.

, Bondarenko

Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction.

J Am Coll Cardiol 2003; 42: 895–901.

90.

Wagner

, Mahrholdt

, Holly

T.A.

Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: An imaging study.

Lancet 2003; 361: 374–9.

91.

Kitagawa

, Sakuma

, Hirano

Acute myocardial infarction: Myocardial viability assessment in patients early thereafter comparison of contrast-enhanced MR imaging with resting (201)TI SPECT. Single photon emission computed tomography.

Radiology 2003; 226: 138–44.

92.

Lund

G.K.

, Stork

, Saeed

Acute myocardial infarction: Evaluation with first-pass enhancement and delayed enhancement MR imaging compared with TI 201SPECT imaging.

Radiology 2004; 232: 49–57.

93.

De Roos

, Van Rossum

A.C.

, Van der Wall

E.E.

Reperfused and non reperfused myocardial infarction: Potential of gadolinium DTPA enhanced MR imaging.

Radiology 1989; 172: 717–20.

94.

Eichstaedt

H.W.

, Felix

, Dougherty

F.C.

Magnetic resonance imaging in different stages of myocardial infarction using the contrast agent gadolinium DTPA.

Clin Cardiol 1986; 9: 527–35.

95.

De Roos

, Doornbos

, Van der Wall

E.E.

MR imaging of acute myocardial infarction: Value of Gd DTPA. In: Braunwald

, ed. Year book of medicine. Chicago: Year Book Medical Publishers 1989; 323–5.

96.

De Roos

, Doornbos

, Van der Wall

E.E.

MR imaging of acute myocardial infarction: Value of Gd DTPA.

AJR 1988; 150: 531–4.

97.

Wolf

G.L.

Biological basis of proton relaxation. In: Marcus

Schelbert

, Skorton

Wolf

, eds. Cardiac Imaging. Saunders 1991; 40: 759–68.